All In Biotech

Drug Trial Radar · NCT01449461

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)

A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113

Last checked: Nov 19, 2026Latest source record: Aug 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

137

Actual

Start

Sep 20, 2011

Primary completion

Nov 16, 2015

Study completion Feb 18, 2020

Sponsor

Lead sponsor
Ariad PharmaceuticalsTakeda (TAK)
Sponsor type
Industry
First posted
Oct 10, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is 2-fold: initially, in the dose escalation phase, the goal is to determine the safety profile of orally administered brigatinib, including: the maximum tolerated dose (MTD), dose limiting toxicities (DLTs), recommended phase 2 dose (RP2D), and pharmacokinetic (PK) profile. Then, once the RP2D is established, an expansion phase will assess the preliminary anti-tumor activity of brigatinib, both in non-small cell lung cancer (NSCLC) with ALK gene rearrangement (including participants with active brain metastases) or mutated EGFR, and in other cancers with abnormal targets against which brigatinib is active.

Conditions

  • Lymphoma, Large-Cell, Anaplastic
  • Carcinoma, Non-Small-Cell Lung

Interventions

  • BrigatinibDrug

    Brigatinib tablets and capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended Phase 2 Dose (RP2D) of BrigatinibTime frame: 28 days
  2. Objective Response Rate (ORR)Time frame: From Screening and at 8-week intervals thereafter up to end of the study (up to 8.4 years)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.